vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与ONESPAWORLD HOLDINGS Ltd（OSW）财务数据对比。点击上方公司名可切换其他公司
ONESPAWORLD HOLDINGS Ltd的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.6倍（$242.1M vs $152.6M），CATALYST PHARMACEUTICALS, INC.净利率更高（34.5% vs 5.0%，领先29.5%），ONESPAWORLD HOLDINGS Ltd同比增速更快（11.5% vs 7.6%），CATALYST PHARMACEUTICALS, INC.自由现金流更多（$44.9M vs $14.9M），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs 7.1%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
CPRX vs OSW — 直观对比
营收规模更大
OSW
是对方的1.6倍
$152.6M
营收增速更快
OSW
高出3.9%
7.6%
净利率更高
CPRX
高出29.5%
5.0%
自由现金流更多
CPRX
多$30.0M
$14.9M
两年增速更快
CPRX
近两年复合增速
7.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $242.1M |
| 净利润 | $52.7M | $12.1M |
| 毛利率 | 82.9% | — |
| 营业利润率 | 40.5% | 6.8% |
| 净利率 | 34.5% | 5.0% |
| 营收同比 | 7.6% | 11.5% |
| 净利润同比 | -5.8% | -16.2% |
| 每股收益（稀释后） | $0.40 | $0.12 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXOSW
| Q4 25 | $152.6M | $242.1M | ||
| Q3 25 | $148.4M | $258.5M | ||
| Q2 25 | $146.6M | $240.7M | ||
| Q1 25 | $141.4M | $219.6M | ||
| Q4 24 | $141.8M | $217.2M | ||
| Q3 24 | $128.7M | $241.7M | ||
| Q2 24 | $122.7M | $224.9M | ||
| Q1 24 | $98.5M | $211.2M |
净利润CPRXOSW
| Q4 25 | $52.7M | $12.1M | ||
| Q3 25 | $52.8M | $24.3M | ||
| Q2 25 | $52.1M | $19.9M | ||
| Q1 25 | $56.7M | $15.3M | ||
| Q4 24 | $55.9M | $14.4M | ||
| Q3 24 | $43.9M | $21.6M | ||
| Q2 24 | $40.8M | $15.8M | ||
| Q1 24 | $23.3M | $21.2M |
毛利率CPRXOSW
| Q4 25 | 82.9% | — | ||
| Q3 25 | 84.7% | — | ||
| Q2 25 | 85.9% | — | ||
| Q1 25 | 87.3% | — | ||
| Q4 24 | 84.7% | — | ||
| Q3 24 | 85.0% | — | ||
| Q2 24 | 87.4% | — | ||
| Q1 24 | 87.3% | — |
营业利润率CPRXOSW
| Q4 25 | 40.5% | 6.8% | ||
| Q3 25 | 44.7% | 10.2% | ||
| Q2 25 | 45.2% | 9.2% | ||
| Q1 25 | 44.8% | 7.7% | ||
| Q4 24 | 44.3% | 7.9% | ||
| Q3 24 | 39.6% | 10.3% | ||
| Q2 24 | 44.2% | 8.4% | ||
| Q1 24 | 27.5% | 8.0% |
净利率CPRXOSW
| Q4 25 | 34.5% | 5.0% | ||
| Q3 25 | 35.6% | 9.4% | ||
| Q2 25 | 35.6% | 8.3% | ||
| Q1 25 | 40.1% | 7.0% | ||
| Q4 24 | 39.4% | 6.6% | ||
| Q3 24 | 34.1% | 8.9% | ||
| Q2 24 | 33.2% | 7.0% | ||
| Q1 24 | 23.6% | 10.0% |
每股收益（稀释后）CPRXOSW
| Q4 25 | $0.40 | $0.12 | ||
| Q3 25 | $0.42 | $0.23 | ||
| Q2 25 | $0.41 | $0.19 | ||
| Q1 25 | $0.45 | $0.15 | ||
| Q4 24 | $0.44 | $0.13 | ||
| Q3 24 | $0.35 | $0.20 | ||
| Q2 24 | $0.33 | $0.15 | ||
| Q1 24 | $0.19 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $16.3M |
| 总债务越低越好 | — | $84.0M |
| 股东权益账面价值 | $954.3M | $542.6M |
| 总资产 | $1.1B | $707.1M |
| 负债/权益比越低杠杆越低 | — | 0.15× |
8季度趋势，按日历期对齐
现金及短期投资CPRXOSW
| Q4 25 | $709.2M | $16.3M | ||
| Q3 25 | $689.9M | $29.6M | ||
| Q2 25 | $652.8M | $35.0M | ||
| Q1 25 | $580.7M | $22.6M | ||
| Q4 24 | $517.6M | $57.4M | ||
| Q3 24 | $442.3M | $48.8M | ||
| Q2 24 | $375.7M | $62.5M | ||
| Q1 24 | $310.4M | $65.4M |
总债务CPRXOSW
| Q4 25 | — | $84.0M | ||
| Q3 25 | — | $85.2M | ||
| Q2 25 | — | $96.2M | ||
| Q1 25 | — | $97.4M | ||
| Q4 24 | — | $98.6M | ||
| Q3 24 | — | $98.7M | ||
| Q2 24 | — | $123.8M | ||
| Q1 24 | — | $138.6M |
股东权益CPRXOSW
| Q4 25 | $954.3M | $542.6M | ||
| Q3 25 | $920.2M | $552.8M | ||
| Q2 25 | $856.0M | $548.3M | ||
| Q1 25 | $794.3M | $530.6M | ||
| Q4 24 | $727.6M | $554.5M | ||
| Q3 24 | $660.9M | $540.1M | ||
| Q2 24 | $608.7M | $532.7M | ||
| Q1 24 | $561.4M | $515.5M |
总资产CPRXOSW
| Q4 25 | $1.1B | $707.1M | ||
| Q3 25 | $1.1B | $732.6M | ||
| Q2 25 | $971.9M | $731.8M | ||
| Q1 25 | $908.9M | $708.7M | ||
| Q4 24 | $851.4M | $746.4M | ||
| Q3 24 | $772.0M | $734.0M | ||
| Q2 24 | $706.4M | $756.8M | ||
| Q1 24 | $646.7M | $763.6M |
负债/权益比CPRXOSW
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | 0.15× | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.18× | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | 0.18× | ||
| Q2 24 | — | 0.23× | ||
| Q1 24 | — | 0.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $20.0M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | $14.9M |
| 自由现金流率自由现金流/营收 | 29.4% | 6.2% |
| 资本支出强度资本支出/营收 | 0.0% | 2.1% |
| 现金转化率经营现金流/净利润 | 0.85× | 1.65× |
| 过去12个月自由现金流最近4个季度 | — | $68.4M |
8季度趋势，按日历期对齐
经营现金流CPRXOSW
| Q4 25 | $44.9M | $20.0M | ||
| Q3 25 | $32.4M | $33.2M | ||
| Q2 25 | $71.3M | $20.3M | ||
| Q1 25 | $60.0M | $10.1M | ||
| Q4 24 | $70.9M | $16.6M | ||
| Q3 24 | $72.9M | $28.6M | ||
| Q2 24 | $64.1M | $18.7M | ||
| Q1 24 | $31.9M | $15.0M |
自由现金流CPRXOSW
| Q4 25 | $44.9M | $14.9M | ||
| Q3 25 | — | $27.6M | ||
| Q2 25 | $71.3M | $17.6M | ||
| Q1 25 | — | $8.4M | ||
| Q4 24 | $70.8M | $13.2M | ||
| Q3 24 | $72.6M | $27.5M | ||
| Q2 24 | $64.1M | $17.6M | ||
| Q1 24 | $31.7M | $13.7M |
自由现金流率CPRXOSW
| Q4 25 | 29.4% | 6.2% | ||
| Q3 25 | — | 10.7% | ||
| Q2 25 | 48.6% | 7.3% | ||
| Q1 25 | — | 3.8% | ||
| Q4 24 | 49.9% | 6.1% | ||
| Q3 24 | 56.4% | 11.4% | ||
| Q2 24 | 52.3% | 7.8% | ||
| Q1 24 | 32.2% | 6.5% |
资本支出强度CPRXOSW
| Q4 25 | 0.0% | 2.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.1% | ||
| Q1 25 | 0.0% | 0.8% | ||
| Q4 24 | 0.1% | 1.5% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | 0.0% | 0.5% | ||
| Q1 24 | 0.2% | 0.6% |
现金转化率CPRXOSW
| Q4 25 | 0.85× | 1.65× | ||
| Q3 25 | 0.61× | 1.36× | ||
| Q2 25 | 1.37× | 1.02× | ||
| Q1 25 | 1.06× | 0.66× | ||
| Q4 24 | 1.27× | 1.15× | ||
| Q3 24 | 1.66× | 1.33× | ||
| Q2 24 | 1.57× | 1.19× | ||
| Q1 24 | 1.37× | 0.71× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
